ascentage.com - Nilai perusahaan marang pendapatan AAPGV

Ascentage Pharma Group is a reputable developer of targeted oncology therapies creating innovative treatments for resistant leukemias. Software robots are currently being implemented to process clinical data arrays. The company's enterprise value based on revenue, excluding debt, reflects market dynamics where the value of 12973.75 corresponds to the current metric. Brand equity is based on partner payments and the commercialization of drugs in the US and China.
Ascentage Pharma Group International - rincian analitis lan metrik utama (AAPGV)

The selection of high-quality issuers is based on comparing the market value of a business with its actual ability to generate income. The EV/Sales ratio measures the enterprise value relative to sales volume, excluding the impact of debt load, which allows for an assessment of the monetization efficiency of Ascentage Pharma Group (AAPGV) patents for the drug Lisoftus and the potential of their targeted developments through the price action on this chart.